Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2010 /
Issues with reliability in HER2 testing and avastin for metastatic breast cancer

8th - 12th Dec 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.01.11
Views: 7532
Rating:

Dr Edith Perez – Mayo Clinic, Florida, USA

Dr Perez talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about a debate she took part in on the use of Avastin (Bevacizumab) for metastatic breast cancer and also her recent analysis of HER2 breast cancer tests, revealing issues with reliability. Results for testing breast tumours for HER2 proteins and genes are most often straightforward when one piece of tumour is analyzed. However tumours can be diverse and Dr Perez’s research found that HER2 results can vary in up to 10 percent of patients when several tumour blocks are analysed. This could have impact in the clinic.

Categories:

Policy · Breast · Diagnostics · SABCS 2010

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation